I-Mab Advances AbbVie-Partnered CD-47 Candidate

Shanghai 's I-Mab reported clinical trial progress for its "highly differentiated" anti-CD47 mAb lemzoparlimab. In September, I-Mab out-licensed ex-China rights for the candidate to AbbVie in a deal worth up to $2 billion. In a US trial, lemzoparlimab is being tested with Rituxan® for non-Hodgkin lymphoma and with Keytruda® in solid tumors. The NHL trial is being conducted in the US and China , while the solid tumor trial is a China-only study. More details.... Stock Symbols: (NSDQ: IMAB) (NYSE: AZN) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.